Return
Tumor Microenvironment-Rearranging Nanoassemblies Overcome Angiogenesis-Immunotherapy Resistance to Potentiate Osteosarcoma Treatment
Z
X
W
H
W
Y
H
W
DOI:10.1016/j.mtbio.2026.103528.png)
Abstract
En 中文
• Regorafenib demonstrates immunomodulatory activity within the osteosarcoma microenvironment. • The hypoxic tumor microenvironment induced by anti-angiogenic therapy, such as regorafenib, might foster immunosuppressive surrounding, thereby offsetting the drug's direct therapeutic benefits. • Reg@CeO2@HA nanoplatform could overcome the limitations of anti-angiogenic monotherapy through normalizing the Tumor Milieu. • Reg@CeO2@HA nanoplatform could coordinate with PD-L1 blockade to reinvigorate cancer immunotherapy.
Keywords:
Anti-angiogenesis
Immunotherapy
Hypoxia mitigation
ROS clearance
Osteosarcoma
Journal
IF:
10.2
Papers:
3.6K
Citations:
9.5K
